The risks of continuing trastuzumab treatment in HER-2 positive breast cancer after the development of asymptomatic left ventricular dysfunction

Back

HFA Premium Access

The risks of continuing trastuzumab treatment in HER-2 positive breast cancer after the development of asymptomatic left ventricular dysfunction

Session: Cardiovascular disease in special populations - cardio-oncology (1)

Topic: Cardio-Oncology

Speaker: Doctor M. Dominique Joseph (Moscow, RU)

Event: Heart Failure 2024

Congress Presentation

About the speaker

Doctor Merithza Dominique Joseph

RUDN University, Moscow (Russian Federation)

0 follower

7 more presentations in this session

Cardiac manifestations in patients with systemic sclerosis

Speaker: Associate Professor V. Stoickov (Niska Banja, RS)

Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies

Speaker: Doctor A. Abiodun (London, GB)

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

Speaker: Doctor N. Maurea (Naples, IT)

Patients with non-Hodgkin's lymphoma treated with CAR T-cell therapy are at risk of impaired left ventricular function

Speaker: Miss E. Polomski (Leiden, NL)

Fructose exacerbates anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: new roles of sweeteners in cardio-oncology

Speaker: Doctor V. Quagliariello (Naples, IT)

Access the full session

Cardiovascular disease in special populations - cardio-oncology (1)

Speakers: Doctor M. Dominique Joseph, Associate Professor V. Stoickov, Doctor A. Abiodun, Doctor N. Maurea, Miss E. Polomski...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources